Prognia
Drug Database
🇪🇺EU · EMAApplication withdrawnATC: L01XC03

Hervelous(trastuzumab)

Stomach Neoplasms;Breast Neoplasms

Marketing Authorisation Holder: Prestige Biopharma Belgium

INN: trastuzumab

Indication

Treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Hervelous — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.